Skip to content
Toggle main navigation
PURPOSE logo
PURPOSE logo
  • Home
  • Events
  • Opportunities
  • News & Publications
  • T90/R90 HEAL Pain Cohort Program
  • Mobile App
  • About
  • Exhibit
  • Affiliate Networks
    • Music4Pain (U24)
    • ENSEMBLE Network (U24)
    • Pain Research Forum (PRF)
    • ForceNET (U24)
    • NeuronS_MATTR (U24)
    • SPINEWORK Network (U24)
    Log in
    Request to Join

    News & Publications

    Do you have news or publications to share with the PURPOSE Network? Submit your news below.

    Submit Your News or Publication
    All
    Acquired Cognitive Impairment
    Acupuncture
    Addiction
    Ageing
    Alcohol Use / Alcohol Use Disorder (AUD)
    Analgesics
    Analgesics, Topical
    Anatomy
    Anesthesia, General
    Anesthesia, Intravenous regional
    Anesthesia, Local
    Anesthesia, Spinal
    Animal Models
    Anxiety
    Arthritis, Rheumatoid
    See all

    Highlighted News

    Results (7)

    Questionnaire-based nociplastic-like and neuropathic-like pain profiles in rheumatoid arthritis: a multicenter cross-sectional study

    Questionnaire-based nociplastic-like and neuropathic-like pain profiles in rheumatoid arthritis: a multicenter cross-sectional study

    Clin Rheumatol. 2026 Nov 17. doi: 10.1007/s10067-026-08546-5. Online ahead of print.ABSTRACTINTRODUCTION/OBJECTIVES: Pain in rheumatoid arthritis (RA) is traditionally interpreted as a consequence of inflammatory and structural mechanisms; however, neuropathic-like and nociplastic-like features may contribute to persistent symptoms and clinical heterogeneity. This study aimed to describe the distr
    November 18, 2026
    Cannabinoids for pain management in rheumatoid arthritis: a scoping review of clinical evidence and mechanisms

    Cannabinoids for pain management in rheumatoid arthritis: a scoping review of clinical evidence and mechanisms

    Rheumatol Int. 2026 Oct 5;46(10):275. doi: 10.1007/s00296-026-06314-x.ABSTRACTPersistent pain remains a major unmet need in rheumatoid arthritis (RA), even in patients with adequately controlled inflammatory disease. Cannabinoids have been proposed as potential modulators of pain and inflammation, but their clinical role in RA remains uncertain. To map and critically appraise the available clinica
    October 5, 2026
    Now Available: Exploring Pain Episode 7 – Pain Mechanisms and Treatment

    Now Available: Exploring Pain Episode 7 – Pain Mechanisms and Treatment

    New Video Available: Pain Mechanisms and TreatmentWatch the full presentation now in the Media CenterIn Episode 7 of the Exploring Pain series, host Laura Wandner, PhD, sits down with Ted Price, PhD, Director of the Center for Advanced Pain Studies at UT Dallas, to explore how molecular neuroscience is advancing precision pain medicine. Price highlights single-cell transcriptomic and proteomic fin
    August 25, 2026
    Real-world clinical outcomes of patients with disproportionate articular pain in rheumatoid arthritis: ANSWER cohort study

    Real-world clinical outcomes of patients with disproportionate articular pain in rheumatoid arthritis: ANSWER cohort study

    Scand J Rheumatol. 2026 Jun 19:1-12. doi: 10.1080/03009742.2026.2680764. Online ahead of print.ABSTRACTPURPOSE: In rheumatoid arthritis (RA), some patients experience joint pain that is disproportionate to the number of swollen joints, known as disproportionate articular pain (DP). This study aimed to clarify the prevalence and persistence of DP and to compare the outcomes across biological and ta
    June 19, 2026
    Multisite Chronic Pain Reveals Neuro-Immune-Metabolic Dysregulation across Rheumatoid Arthritis and Depression

    Multisite Chronic Pain Reveals Neuro-Immune-Metabolic Dysregulation across Rheumatoid Arthritis and Depression

    Research (Wash D C). 2026 Jun 17;9:1298. doi: 10.34133/research.1298. eCollection 2026.ABSTRACTMultisite chronic pain (MCP) frequently co-occurs with immune and depressive disorders, yet whether it reflects coordinated cross-domain multi-omic dysregulation remains unknown. Using UK Biobank data (19,484 baseline participants; 32,870 to 399,476 for 15.9-year follow-up), we identified MCP-related mul
    June 19, 2026
    Cerebral Pain Processing Following TNFalpha Inhibitor Treatment in Rheumatoid Arthritis: A Randomized Double-Blind Placebo-Controlled fMRI Study

    Cerebral Pain Processing Following TNFalpha Inhibitor Treatment in Rheumatoid Arthritis: A Randomized Double-Blind Placebo-Controlled fMRI Study

    ACR Open Rheumatol. 2026 May;8(5):e90069. doi: 10.1002/acr2.90069.ABSTRACTOBJECTIVE: This study investigated the effects of tumor necrosis factor α (TNFα) blockade treatment, adalimumab (ADA), on cerebral pain processing in relevant brain regions in patients with rheumatoid arthritis (RA). Its secondary aim was to identify pretreatment markers in cerebral pain processing that might predict treatme
    May 20, 2026
    The effect of tumor necrosis factor-alpha on rheumatoid arthritis-related pain: overview of evidence and mechanistic pathways

    The effect of tumor necrosis factor-alpha on rheumatoid arthritis-related pain: overview of evidence and mechanistic pathways

    Croat Med J. 2026 Apr 30;67(2):112-131.ABSTRACTRheumatoid arthritis (RA) is a chronic inflammatory disease characterized by debilitating pain and progressive joint destruction. Tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine, has been implicated in modulating both peripheral and central pain pathways. TNF-α inhibitors, initially developed to halt structural damage in RA, have
    May 11, 2026
    Contact
    Neurovations Education
    [email protected]

    United States

    PURPOSE@PainResearchers.com
    707-260-0848
    Links
    • NIH HEAL Initiative
    • Research in Pain Management